Advertisement

Breast cancer radiotherapy: Is it time to rethink the indication?

Published:October 17, 2022DOI:https://doi.org/10.1016/j.radonc.2022.10.009
      Based on our recent published paper [
      • Overgaard M.
      • Nielsen H.M.
      • Tramm T.
      • Højris I.
      • Grantzau T.L.
      • Alsner J.
      • et al.
      Postmastectomy radiotherapy in high-risk breast cancer patients given adjuvant systemic therapy. A 30-year long-term report from the Danish breast cancer cooperative group DBCG 82bc trial.
      ] Lazzari et al. [
      • Lazzari G.
      • Rago L.
      • Solazzo A.P.
      • Benevento I.
      • Montagna A.
      • Castaldo G.
      • et al.
      Adjuvant chemotherapy and hypofractionated whole breast cancer radiotherapy: is it time to rethink the sequencing?.
      ] raise the general question of whether we should rethink the sequencing of radiotherapy and systemic treatment in early breast cancer (BC), as recently discussed elsewhere [
      • Alcorn S.R.
      • Wright J.L.
      Toxicity and timing of breast radiation therapy with overlapping systemic therapies.
      ]. The complexity in treating patients with BC has increased considerably since the accrual of patients in the DBCG 82b&c trial. There are several important results from the trial, that are still valid today, but also pivotal differences making extrapolation of the DBCG 82b&c results up to 2020’s difficult.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Radiotherapy and Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Overgaard M.
        • Nielsen H.M.
        • Tramm T.
        • Højris I.
        • Grantzau T.L.
        • Alsner J.
        • et al.
        Postmastectomy radiotherapy in high-risk breast cancer patients given adjuvant systemic therapy. A 30-year long-term report from the Danish breast cancer cooperative group DBCG 82bc trial.
        Radiother Oncol. 2022; 170: 4-13https://doi.org/10.1016/j.radonc.2022.03.008
        • Lazzari G.
        • Rago L.
        • Solazzo A.P.
        • Benevento I.
        • Montagna A.
        • Castaldo G.
        • et al.
        Adjuvant chemotherapy and hypofractionated whole breast cancer radiotherapy: is it time to rethink the sequencing?.
        Radiother Oncol. 2002; (current issue)
        • Alcorn S.R.
        • Wright J.L.
        Toxicity and timing of breast radiation therapy with overlapping systemic therapies.
        Int J Radiat Oncol Biol Phys. 2022; 114: 377-381https://doi.org/10.1016/j.ijrobp.2022.05.024
        • Offersen B.V.
        • Alsner J.
        • Nielsen H.M.
        • Jakobsen E.H.
        • Nielsen M.H.
        • Krause M.
        • et al.
        Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomized phase III Trial: The DBCG HYPO trial.
        J Clin Oncol. 2020; 38: 3615-3625https://doi.org/10.1200/JCO.20.01363
        • Offersen B.V.
        • Alsner J.
        • Nielsen H.M.
        • Jakobsen E.H.
        • Nielsen M.H.
        • Stenbygaard L.
        • et al.
        Partial breast irradiation versus whole breast irradiation for early breast cancer patients in a randomized phase III trial: The Danish breast cancer group partial breast irradiation trial.
        J Clin Oncol. 2022; : JCO2200451https://doi.org/10.1200/JCO.22.00451
        • Coles C.E.
        • Griffin C.L.
        • Kirby A.M.
        • Titley J.
        • Agrawal R.K.
        • Alhasso A.
        • et al.
        Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial.
        Lancet. 2017; 390: 1048-1060https://doi.org/10.1016/S0140-6736(17)31145-5
        • Murray Brunt A.
        • Haviland J.S.
        • Wheatley D.A.
        • Sydenham M.A.
        • Alhasso A.
        • Bloomfield D.J.
        • et al.
        Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.
        Lancet. 2020; 395: 1613-1626https://doi.org/10.1016/S0140-6736(20)30932-6
        • Thorsen L.B.J.
        • Overgaard J.
        • Matthiessen L.W.
        • Berg M.
        • Stenbygaard L.
        • Pedersen A.N.
        • et al.
        Internal mammary node irradiation in patients with node-positive early breast Cancer: fifteen-year results from the Danish breast cancer group internal mammary node study.
        J Clin Oncol. 2022; : JCO2200044https://doi.org/10.1200/JCO.22.00044
        • Whelan T.J.
        • Olivotto I.A.
        • Parulekar W.R.
        • Ackerman I.
        • Chua B.H.
        • Nabid A.
        • et al.
        Regional nodal irradiation in early-stage breast cancer.
        N Engl J Med. 2015; 373: 307-316https://doi.org/10.1056/NEJMoa1415340
        • Kaidar-Person O.
        • Fortpied C.
        • Hol S.
        • Weltens C.
        • Kirkove C.
        • Budach V.
        • et al.
        The association of internal mammary and medial supraclavicular lymph node radiation technique with clinical outcomes: Results from the EORTC 22922/10925 randomised trial.
        Radiother Oncol. 2022; 172: 99-110https://doi.org/10.1016/j.radonc.2022.05.006
        • Poortmans P.M.
        • Weltens C.
        • Fortpied C.
        • Kirkove C.
        • Peignaux-Casasnovas K.
        • Budach V.
        • et al.
        Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial.
        Lancet Oncol. 2020; 21: 1602-1610https://doi.org/10.1016/S1470-2045(20)30472-1
      1. The Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Radiotherapy to Regional Nodes in Early Breast Cancer: An Individual Patient Data Meta-Analysis of 13,000 Women in 14 Trials. Cancer Res 2019;79: (4_Supplement): GS4-02. https://doi.org/10.1158/1538-7445.SABCS18-GS4-02.

        • Offersen B.V.
        • Overgaard J.
        Breast cancer radiation therapy.
        Lancet. 2020; 396: 1558https://doi.org/10.1016/S0140-6736(20)32322-9
        • Grantzau T.
        • Overgaard J.
        Risk of second non-breast cancer after radiotherapy for breast cancer: a systematic review and meta-analysis of 762,468 patients.
        Radiother Oncol. 2015; 114: 56-65https://doi.org/10.1016/j.radonc.2014.10.004
        • Milo M.L.H.
        • Thorsen L.B.J.
        • Johnsen S.P.
        • Nielsen K.M.
        • Valentin J.B.
        • Alsner J.
        • et al.
        Risk of coronary artery disease after adjuvant radiotherapy in 29,662 early breast cancer patients: A population-based Danish Breast Cancer Group study.
        Radiother Oncol. 2021; 157: 106-113https://doi.org/10.1016/j.radonc.2021.01.010
        • Finnegan R.
        • Lorenzen E.L.
        • Dowling J.
        • Jensen I.
        • Berg M.
        • Thomsen M.S.
        • et al.
        Analysis of cardiac substructure dose in a large, multi-centre danish breast cancer cohort (the DBCG HYPO trial): Trends and predictive modelling.
        Radiother Oncol. 2020; 153: 130-138https://doi.org/10.1016/j.radonc.2020.09.004
        • Lorenzen E.L.
        • Christian Rehammar J.
        • Jensen M.B.
        • Ewertz M.
        • Brink C.
        Radiation-induced risk of ischemic heart disease following breast cancer radiotherapy in Denmark, 1977–2005.
        Radiother Oncol. 2020; 152: 103-110https://doi.org/10.1016/j.radonc.2020.08.007
        • Thomsen M.S.
        • Alsner J.
        • Nielsen H.M.
        • Jakobsen E.H.
        • Nielsen M.H.
        • Moeller M.
        • et al.
        Volume matters: Breast induration is associated with irradiated breast volume in the Danish Breast Cancer Group phase III randomized Partial Breast Irradiation trial.
        Radiother Oncol. 2022; (in press)
        • Laurberg T.
        • Lyngholm C.D.
        • Christiansen P.
        • Alsner J.
        • Overgaard J.
        Long-term age-dependent failure pattern after breast-conserving therapy or mastectomy among Danish lymph-node-negative breast cancer patients.
        Radiother Oncol. 2016; 120: 98-106https://doi.org/10.1016/j.radonc.2016.05.006
        • Overgaard J.
        • Aznar M.C.
        • Bacchus C.
        • Coppes R.P.
        • Deutsch E.
        • Georg D.
        • et al.
        Personalised radiation therapy taking both the tumour and patient into consideration.
        Radiother Oncol. 2022; 166: A1-A5https://doi.org/10.1016/j.radonc.2022.01.010
        • Tramm T.
        • Vinter H.
        • Vahl P.
        • Özcan D.
        • Alsner J.
        • Overgaard J.
        Tumor-infiltrating lymphocytes predict improved overall survival after post-mastectomy radiotherapy: a study of the randomized DBCG82bc cohort.
        Acta Oncol. 2022; 61: 153-162https://doi.org/10.1080/0284186X.2021.1989629